{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:02:11Z","timestamp":1794852131819,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mice were immunized with Adenovirus expressing the H1-con, H2-con, H3-con and H5-con HA consensus genes in combination (multivalent) and compared to mice immunized with the traditional 2010\u20132011 FluZone and FluMist seasonal vaccines. Immunized mice were challenged with 10\u2013100 MLD<jats:sub>50<\/jats:sub> of H1N1, H3N1, H3N2 and H5N1 influenza viruses. The traditional vaccines induced robust levels of HA inhibition (HI) titers, but failed to protect against five different heterologous lethal influenza challenges. Conversely, the multivalent consensus vaccine (1\u2009\u00d7\u200910<jats:sup>10<\/jats:sup> virus particles (vp)\/mouse) induced protective HI titers of \u226540 against 8 of 10 influenza viruses that represent a wide degree of divergence within the HA subtypes and protected 100% of mice from 8 of 9 lethal heterologous influenza virus challenges. The vaccine protection was dose dependent, in general, and a dose as low as 5\u2009\u00d7\u200910<jats:sup>7<\/jats:sup> vp\/mouse still provided 100% survival against 7 of 9 lethal heterologous influenza challenges. These data indicate that very low doses of Adenovirus-vectored consensus vaccines induce superior levels of immunity against a wide divergence of influenza subtypes as compared to traditional vaccines. These doses are scalable and translatable to humans and may provide the foundation for complete and long-lasting anti-influenza immunity.<\/jats:p>","DOI":"10.1038\/s41598-017-14891-y","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T09:45:31Z","timestamp":1509097531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine"],"prefix":"10.1038","volume":"7","author":[{"given":"Amy","family":"Lingel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna L.","family":"Bullard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"14891_CR1","first-page":"1151","volume":"63","author":"C Reed","year":"2014","unstructured":"Reed, C. et al. Estimated influenza illnesses and hospitalizations averted by vaccination\u2013United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep \n                           63, 1151\u20131154 (2014).","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"14891_CR2","first-page":"583","volume":"64","author":"GD Appiah","year":"2015","unstructured":"Appiah, G. D. et al. Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep \n                           64, 583\u2013590 (2015).","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"14891_CR3","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","volume":"34","author":"F Berlanda Scorza","year":"2016","unstructured":"Berlanda Scorza, F., Tsvetnitsky, V. & Donnelly, J. J. Universal influenza vaccines: Shifting to better vaccines. Vaccine \n                           34, 2926\u20132933, https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.085 (2016).","journal-title":"Vaccine"},{"key":"14891_CR4","doi-asserted-by":"publisher","first-page":"e0140702","DOI":"10.1371\/journal.pone.0140702","volume":"10","author":"RJ Webby","year":"2015","unstructured":"Webby, R. J. & Weaver, E. A. Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses. PloS one \n                           10, e0140702, https:\/\/doi.org\/10.1371\/journal.pone.0140702 (2015).","journal-title":"PloS one"},{"key":"14891_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/irv.12074","volume":"7","author":"MD Van Kerkhove","year":"2013","unstructured":"Van Kerkhove, M. D., Hirve, S., Koukounari, A., Mounts, A. W. & group, H. N. P. S. W. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza and other respiratory viruses \n                           7, 872\u2013886, https:\/\/doi.org\/10.1111\/irv.12074 (2013).","journal-title":"Influenza and other respiratory viruses"},{"issue":"Suppl 1","key":"14891_CR6","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1093\/cid\/ciq012","volume":"52","author":"SS Shrestha","year":"2011","unstructured":"Shrestha, S. S. et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis \n                           52(Suppl 1), S75\u201382, https:\/\/doi.org\/10.1093\/cid\/ciq012 (2011).","journal-title":"Clin Infect Dis"},{"key":"14891_CR7","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1038\/nm1141","volume":"10","author":"P Palese","year":"2004","unstructured":"Palese, P. Influenza: old and new threats. Nature medicine \n                           10, S82\u201387, https:\/\/doi.org\/10.1038\/nm1141 (2004).","journal-title":"Nature medicine"},{"key":"14891_CR8","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1128\/JVI.78.17.8951-8959.2004","volume":"78","author":"AS Lipatov","year":"2004","unstructured":"Lipatov, A. S. et al. Influenza: emergence and control. Journal of virology \n                           78, 8951\u20138959, https:\/\/doi.org\/10.1128\/JVI.78.17.8951-8959.2004 (2004).","journal-title":"Journal of virology"},{"key":"14891_CR9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/JVI.73.2.1146-1155.1999","volume":"73","author":"M Matrosovich","year":"1999","unstructured":"Matrosovich, M., Zhou, N., Kawaoka, Y. & Webster, R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Journal of virology \n                           73, 1146\u20131155 (1999).","journal-title":"Journal of virology"},{"key":"14891_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12275-017-7062-7","volume":"55","author":"R Harfoot","year":"2017","unstructured":"Harfoot, R. & Webby, R. J. H5 influenza, a global update. J Microbiol \n                           55, 196\u2013203, https:\/\/doi.org\/10.1007\/s12275-017-7062-7 (2017).","journal-title":"J Microbiol"},{"key":"14891_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1126\/science.1213362","volume":"336","author":"S Herfst","year":"2012","unstructured":"Herfst, S. et al. Airborne transmission of influenza A\/H5N1 virus between ferrets. Science (New York, N.Y) \n                           336, 1534\u20131541, https:\/\/doi.org\/10.1126\/science.1213362 (2012).","journal-title":"Science (New York, N.Y)"},{"key":"14891_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature10831","volume":"486","author":"M Imai","year":"2012","unstructured":"Imai, M. et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets. Nature \n                           486, 420\u2013428, https:\/\/doi.org\/10.1038\/nature10831 (2012).","journal-title":"Nature"},{"key":"14891_CR13","doi-asserted-by":"publisher","unstructured":"Gautret, P. et al. Emerging viral respiratory tract infections-environmental risk factors and transmission. Lancet Infect Dis, https:\/\/doi.org\/10.1016\/S1473-3099(14)70831-X (2014).","DOI":"10.1016\/S1473-3099(14)70831-X"},{"key":"14891_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","volume":"12","author":"MT Osterholm","year":"2012","unstructured":"Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia, E. A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis \n                           12, 36\u201344, https:\/\/doi.org\/10.1016\/S1473-3099(11)70295-X (2012).","journal-title":"Lancet Infect Dis"},{"key":"14891_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.vaccine.2012.12.013","volume":"31","author":"CA DiazGranados","year":"2013","unstructured":"DiazGranados, C. A. et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine \n                           31, 861\u2013866, https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.013 (2013).","journal-title":"Vaccine"},{"key":"14891_CR16","doi-asserted-by":"publisher","unstructured":"Diseases, C. o. I. Recommendations for Prevention and Control of Influenza in Children, 2014-2015. Pediatrics, https:\/\/doi.org\/10.1542\/peds.2014-2413 (2014).","DOI":"10.1542\/peds.2014-2413"},{"key":"14891_CR17","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.1016\/j.vaccine.2009.07.007","volume":"27","author":"W Fiers","year":"2009","unstructured":"Fiers, W. et al. M2e-based universal influenza A vaccine. Vaccine \n                           27, 6280\u20136283, https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.007 (2009).","journal-title":"Vaccine"},{"key":"14891_CR18","doi-asserted-by":"publisher","unstructured":"Mullarkey, C. E. et al. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio \n                           7, https:\/\/doi.org\/10.1128\/mBio.01624-16 (2016).","DOI":"10.1128\/mBio.01624-16"},{"key":"14891_CR19","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1128\/JVI.02481-15","volume":"90","author":"R Nachbagauer","year":"2015","unstructured":"Nachbagauer, R. et al. Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. Journal of virology \n                           90, 3268\u20133273, https:\/\/doi.org\/10.1128\/JVI.02481-15 (2015).","journal-title":"Journal of virology"},{"key":"14891_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep22666","volume":"6","author":"SA Valkenburg","year":"2016","unstructured":"Valkenburg, S. A. et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci Rep \n                           6, 22666, https:\/\/doi.org\/10.1038\/srep22666 (2016).","journal-title":"Sci Rep"},{"key":"14891_CR21","doi-asserted-by":"publisher","unstructured":"Di Mario, G. et al. Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. Pathog Glob Health, 1\u20137, https:\/\/doi.org\/10.1080\/20477724.2016.1275465 (2017).","DOI":"10.1080\/20477724.2016.1275465"},{"key":"14891_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep39665","volume":"6","author":"WT Yang","year":"2016","unstructured":"Yang, W. T. et al. Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum. Sci Rep \n                           6, 39665, https:\/\/doi.org\/10.1038\/srep39665 (2016).","journal-title":"Sci Rep"},{"key":"14891_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1128\/JVI.79.2.1154-1163.2005","volume":"79","author":"F Gao","year":"2005","unstructured":"Gao, F. et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. Journal of virology \n                           79, 1154\u20131163 (2005).","journal-title":"Journal of virology"},{"key":"14891_CR24","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.1128\/JVI.02484-05","volume":"80","author":"EA Weaver","year":"2006","unstructured":"Weaver, E. A. et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. Journal of virology \n                           80, 6745\u20136756 (2006).","journal-title":"Journal of virology"},{"key":"14891_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/aid.2009.0258","volume":"26","author":"EA Weaver","year":"2010","unstructured":"Weaver, E. A., Camacho, Z. T. & Gao, F. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. AIDS Res Hum Retroviruses \n                           26, 577\u2013584, https:\/\/doi.org\/10.1089\/aid.2009.0258 (2010).","journal-title":"AIDS Res Hum Retroviruses"},{"key":"14891_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1073\/pnas.1012457108","volume":"108","author":"MF Ducatez","year":"2011","unstructured":"Ducatez, M. F. et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proceedings of the National Academy of Sciences of the United States of America \n                           108, 349\u2013354, https:\/\/doi.org\/10.1073\/pnas.1012457108 (2011).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"14891_CR27","doi-asserted-by":"publisher","first-page":"e2517","DOI":"10.1371\/journal.pone.0002517","volume":"3","author":"DJ Laddy","year":"2008","unstructured":"Laddy, D. J. et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS one \n                           3, e2517, https:\/\/doi.org\/10.1371\/journal.pone.0002517 (2008).","journal-title":"PloS one"},{"key":"14891_CR28","doi-asserted-by":"publisher","first-page":"e18314","DOI":"10.1371\/journal.pone.0018314","volume":"6","author":"EA Weaver","year":"2011","unstructured":"Weaver, E. A., Rubrum, A. M., Webby, R. J. & Barry, M. A. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PloS one \n                           6, e18314, https:\/\/doi.org\/10.1371\/journal.pone.0018314 (2011).","journal-title":"PloS one"},{"key":"14891_CR29","doi-asserted-by":"publisher","first-page":"ofv067","DOI":"10.1093\/ofid\/ofv067","volume":"2","author":"A Benoit","year":"2015","unstructured":"Benoit, A. et al. Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A\/H3N2 Influenza Disease. Open Forum Infect Dis \n                           2, ofv067, https:\/\/doi.org\/10.1093\/ofid\/ofv067 (2015).","journal-title":"Open Forum Infect Dis"},{"key":"14891_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.vaccine.2016.04.022","volume":"34","author":"A Nagy","year":"2016","unstructured":"Nagy, A. et al. Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge. Vaccine \n                           34, 2537\u20132545, https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.022 (2016).","journal-title":"Vaccine"},{"key":"14891_CR31","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.vaccine.2014.02.038","volume":"32","author":"J Yan","year":"2014","unstructured":"Yan, J. et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine \n                           32, 2833\u20132842, https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.038 (2014).","journal-title":"Vaccine"},{"key":"14891_CR32","doi-asserted-by":"publisher","unstructured":"Bart, P. A. et al. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. The Journal of clinical investigation, https:\/\/doi.org\/10.1172\/JCI75894 (2014).","DOI":"10.1172\/JCI75894"},{"key":"14891_CR33","doi-asserted-by":"publisher","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","volume":"8","author":"A Ouedraogo","year":"2013","unstructured":"Ouedraogo, A. et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PloS one \n                           8, e78679, https:\/\/doi.org\/10.1371\/journal.pone.0078679 (2013).","journal-title":"PloS one"},{"key":"14891_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/infdis\/jis670","volume":"207","author":"LR Baden","year":"2013","unstructured":"Baden, L. R. et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). The Journal of infectious diseases \n                           207, 240\u2013247, https:\/\/doi.org\/10.1093\/infdis\/jis670 (2013).","journal-title":"The Journal of infectious diseases"},{"key":"14891_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jir850","volume":"205","author":"GA O\u2019Hara","year":"2012","unstructured":"O\u2019Hara, G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. The Journal of infectious diseases \n                           205, 772\u2013781, https:\/\/doi.org\/10.1093\/infdis\/jir850 (2012).","journal-title":"The Journal of infectious diseases"},{"key":"14891_CR36","doi-asserted-by":"publisher","first-page":"11756","DOI":"10.1128\/JVI.01460-06","volume":"80","author":"XS He","year":"2006","unstructured":"He, X. S. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. Journal of virology \n                           80, 11756\u201311766, https:\/\/doi.org\/10.1128\/JVI.01460-06 (2006).","journal-title":"Journal of virology"},{"key":"14891_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijid.2014.05.016","volume":"27C","author":"J Li","year":"2014","unstructured":"Li, J., Arevalo, M. T., Chen, Y., Chen, S. & Zeng, M. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases \n                           27C, 37\u201343, https:\/\/doi.org\/10.1016\/j.ijid.2014.05.016 (2014).","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"14891_CR38","doi-asserted-by":"publisher","first-page":"e73313","DOI":"10.1371\/journal.pone.0073313","volume":"8","author":"EA Weaver","year":"2013","unstructured":"Weaver, E. A. & Barry, M. A. Low seroprevalent species D adenovirus vectors as influenza vaccines. PloS one \n                           8, e73313, https:\/\/doi.org\/10.1371\/journal.pone.0073313 (2013).","journal-title":"PloS one"},{"key":"14891_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","volume":"76","author":"V Molinier-Frenkel","year":"2002","unstructured":"Molinier-Frenkel, V. et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. Journal of virology \n                           76, 127\u2013135 (2002).","journal-title":"Journal of virology"},{"key":"14891_CR40","unstructured":"FDA, U. Influenza Virus Vaccine for the 2010-2011 Season,https:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Post-MarketActivities\/LotReleases\/ucm202750.htm (2010)."},{"key":"14891_CR41","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1128\/JVI.00159-10","volume":"84","author":"NA Ilyushina","year":"2010","unstructured":"Ilyushina, N. A. et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol \n                           84, 8607\u20138616 (2010).","journal-title":"J Virol"},{"key":"14891_CR42","unstructured":"pepperchip. PEPperCHIP\u00ae Immunoassay Protocol. http:\/\/www.pepperprint.com\/fileadmin\/user_upload\/documents\/PEPperCHIP_Immunoassay_Protocol_07-2016.pdf (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14891-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:02:23Z","timestamp":1671800543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14891-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14891-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]},"assertion":[{"value":"2 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14912"}}